quotes and stock data may be delayed 15 minutes
52 wk low
52 wk hi
Burn Rate (Qtr)
Click on drug name or indication to see upcoming trial info, prior data, and more general information.
No drug found
We have found any drug for this company yet
Drug | Disease (links)
Stage (next event)
search in progress
Pipeline powered by
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy.
See what the community is saying - click to see full post.